Last 12 months
Inside the activity.
5 purchase rows · 15 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 5 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 4 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 20, 2021 Filed Jan 22, 2021 16:33 UTC |
Pienta KennethChief Medical Officer
|
PurchaseCommon Stock | 2,720 | $15.07 | $40,979.52 |
DisclosureSEC source: 0000899243-21-002947 · doc4.xml · nonDerivative · entry 1 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,720 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.02 to $15.26, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| January 20, 2021 Filed Feb 18, 2021 20:40 UTC Amendment |
Pienta KennethChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,720 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0000899243-21-007230 · doc4a.xml · derivative · entry 3 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,280 Underlying: Common Stock · 2,720 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F2 · shares: This option exercise was omitted from the reporting person's original Form 4. F5 · derivative.exercise_date: The option, representing a right to purchase a total of 20,000 shares, became exercisable in full on November 16, 2017. Read SEC document |
| January 20, 2021 Filed Feb 18, 2021 20:40 UTC Amendment |
Pienta KennethChief Medical Officer
|
SaleCommon Stock | 2,720 | $15.07 | $40,979.52 |
DisclosureSEC source: 0000899243-21-007230 · doc4a.xml · nonDerivative · entry 2 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F3 · kind: This transaction was incorrectly reported using Code "P" in the reporting person's original Form 4. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.02 to $15.26, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| January 20, 2021 Filed Feb 18, 2021 20:40 UTC Amendment |
Pienta KennethChief Medical Officer
|
Exercise / conversionCommon Stock | 2,720 | $2.86 | $7,779.20 |
DisclosureSEC source: 0000899243-21-007230 · doc4a.xml · nonDerivative · entry 1 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F2 · shares: This option exercise was omitted from the reporting person's original Form 4. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:44 UTC |
DRISCOLL FREDERICK WDirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.36 | $0.00 |
DisclosureSEC source: 0000899243-21-000710 · doc4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-03 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 4, 2021. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:46 UTC |
Simon Barry J.Director
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.36 | $0.00 |
DisclosureSEC source: 0000899243-21-000712 · doc4.xml · derivative · entry 1 Simon Barry J. · CIK 0001647994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-03 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 4, 2021. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:39 UTC |
HOWSON TAMAR DDirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.36 | $0.00 |
DisclosureSEC source: 0000899243-21-000700 · doc4.xml · derivative · entry 1 HOWSON TAMAR D · CIK 0001202286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-03 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 4, 2021. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 16:44 UTC |
Kiener Peter ADirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.36 | $0.00 |
DisclosureSEC source: 0000899243-21-000711 · doc4.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-03 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 4, 2021. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 16:39 UTC |
Gray CameronDirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.36 | $0.00 |
DisclosureSEC source: 0000899243-21-000701 · doc4.xml · derivative · entry 1 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-03 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 4, 2021. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:41 UTC |
Morich FrankDirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.36 | $0.00 |
DisclosureSEC source: 0000899243-21-000705 · doc4.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-03 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 4, 2021. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:39 UTC |
Fletcher Aaron G.L.Director
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.36 | $0.00 |
DisclosureSEC source: 0000899243-21-000702 · doc4.xml · derivative · entry 1 Fletcher Aaron G.L. · CIK 0001789490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-03 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 4, 2021. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date. Read SEC document |
| December 02, 2020 Filed Feb 1, 2021 17:41 UTC |
Gray CameronDirector
|
GiftCommon Stock | 271,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003885 · doc5.xml · nonDerivative · entry 4 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Julie Heider Nongrantor Pot Trust under the Julie Heider 2020 Irrevocable Trust Disclosed balance after: 271,000 Read SEC document |
| December 02, 2020 Filed Feb 1, 2021 17:41 UTC |
Gray CameronDirector
|
GiftCommon Stock | 162,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003885 · doc5.xml · nonDerivative · entry 3 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Nongrantor Pot Trust under the Cameron Gray 2020 Irrevocable Trust Disclosed balance after: 162,600 Read SEC document |
| December 02, 2020 Filed Feb 1, 2021 17:41 UTC |
Gray CameronDirector
|
GiftCommon Stock | 162,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003885 · doc5.xml · nonDerivative · entry 2 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Extended Family Nongrantor Pot Trust under the Cameron Gray 2020 Irrevocable Trust Disclosed balance after: 162,600 Read SEC document |
| December 02, 2020 Filed Feb 1, 2021 17:41 UTC |
Gray CameronDirector
|
GiftCommon Stock | 596,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003885 · doc5.xml · nonDerivative · entry 1 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,300 Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 21:09 UTC |
Fletcher Aaron G.L.Director
|
PurchaseCommon Stock | 6,548 | $12.64 | $82,775.89 |
DisclosureSEC source: 0000899243-20-032155 · doc4.xml · nonDerivative · entry 1 Fletcher Aaron G.L. · CIK 0001789490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.335 to $12.92, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 21:08 UTC |
Suri AnishPresident and CSO
|
Tax withholdingCommon Stock | 9,800 | $16.30 | $159,740.00 |
DisclosureSEC source: 0000899243-20-027608 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,091 Read SEC document |
| October 03, 2020 Filed Oct 6, 2020 21:08 UTC |
Suri AnishPresident and CSO
|
Exercise / conversionRestricted Stock Units · Derivative | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027608 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,334 Underlying: Common Stock · 33,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On October 3, 2019, the reporting person was granted 100,000 restricted stock units, scheduled to vest in three equal annual installments beginning on October 3, 2019. F3 · derivative.expiration_date: On October 3, 2019, the reporting person was granted 100,000 restricted stock units, scheduled to vest in three equal annual installments beginning on October 3, 2019. Read SEC document |
| October 03, 2020 Filed Oct 6, 2020 21:08 UTC |
Suri AnishPresident and CSO
|
Exercise / conversionCommon Stock | 33,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-027608 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 16:13 UTC |
Gray CameronDirector
|
PurchaseCommon Stock | 5,000 | $15.30 | $76,500.00 |
DisclosureSEC source: 0000899243-20-026662 · doc4.xml · nonDerivative · entry 2 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 677,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.20 to $15.30, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 16:13 UTC |
Gray CameronDirector
|
PurchaseCommon Stock | 5,000 | $15.00 | $75,000.00 |
DisclosureSEC source: 0000899243-20-026662 · doc4.xml · nonDerivative · entry 1 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 672,500 Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 20:15 UTC |
HOWSON TAMAR DDirector
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $17.21 | $0.00 |
DisclosureSEC source: 0001209191-20-051145 · doc4.xml · derivative · entry 1 HOWSON TAMAR D · CIK 0001202286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-09-17 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning March 17, 2021. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:12 UTC | Tax withholdingCommon Stock | 1,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048212 · doc4.xml · nonDerivative · entry 2 Millar Kerri-Ann · CIK 0001739126 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766 Read SEC document |
|
| August 21, 2020 Filed Aug 25, 2020 20:12 UTC | Exercise / conversionRestricted Stock Units · Derivative | 6,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048212 · doc4.xml · derivative · entry 5 Millar Kerri-Ann · CIK 0001739126 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,334 Underlying: Common Stock · 6,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020. F4 · derivative.expiration_date: Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020. Read SEC document |
|
| August 21, 2020 Filed Aug 25, 2020 20:12 UTC | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048212 · doc4.xml · derivative · entry 4 Millar Kerri-Ann · CIK 0001739126 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020. F4 · derivative.expiration_date: Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020. Read SEC document |
|
| August 21, 2020 Filed Aug 25, 2020 20:12 UTC | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $19.87 | $0.00 |
DisclosureSEC source: 0001209191-20-048212 · doc4.xml · derivative · entry 3 Millar Kerri-Ann · CIK 0001739126 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-08-21 F2 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning February 21, 2021. Read SEC document |
|
| August 21, 2020 Filed Aug 25, 2020 20:12 UTC | Exercise / conversionCommon Stock | 6,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048212 · doc4.xml · nonDerivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
|
| August 05, 2020 Filed Aug 7, 2020 21:44 UTC |
Sandercock ColinSVP, General Counsel and Sec
|
Exercise / conversionStock Option (right to buy) · Derivative | 13,274 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-20-045702 · doc4.xml · derivative · entry 3 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,100 Underlying: Common Stock · 13,274 shares Expires 2024-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:44 UTC |
Sandercock ColinSVP, General Counsel and Sec
|
SaleCommon Stock | 13,274 | $20.00 | $265,480.00 |
DisclosureSEC source: 0001209191-20-045702 · doc4.xml · nonDerivative · entry 2 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,125 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:44 UTC |
Sandercock ColinSVP, General Counsel and Sec
|
Exercise / conversionCommon Stock | 13,274 | $7.50 | $99,555.00 |
DisclosureSEC source: 0001209191-20-045702 · doc4.xml · nonDerivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:41 UTC |
Suri AnishPresident and CSO
|
Exercise / conversionStock Option (right to buy) · Derivative | 800 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0001209191-20-045698 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 800 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:41 UTC |
Suri AnishPresident and CSO
|
SaleCommon Stock | 800 | $20.01 | $16,008.00 |
DisclosureSEC source: 0001209191-20-045698 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,558 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:41 UTC |
Suri AnishPresident and CSO
|
Exercise / conversionCommon Stock | 800 | $6.42 | $5,136.00 |
DisclosureSEC source: 0001209191-20-045698 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2020 Filed Aug 10, 2020 20:03 UTC Amendment |
Sandercock ColinSVP, General Counsel and Sec
|
Exercise / conversionStock Option (right to buy) · Derivative | 13,374 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-20-045921 · doc4a.xml · derivative · entry 3 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 13,374 shares Expires 2024-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 amends and restates the original Form 4 filed on August 7, 2020 (the "Original Form 4") to include 100 Stock Options and shares of Common Stock that were omitted from the Original Form 4 due to clerical error. F4 · derivative.exercise_date: These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018. Read SEC document |
| August 05, 2020 Filed Aug 10, 2020 20:03 UTC Amendment |
Sandercock ColinSVP, General Counsel and Sec
|
SaleCommon Stock | 13,374 | $20.00 | $267,480.00 |
DisclosureSEC source: 0001209191-20-045921 · doc4a.xml · nonDerivative · entry 2 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,125 F1 · security: This Form 4 amends and restates the original Form 4 filed on August 7, 2020 (the "Original Form 4") to include 100 Stock Options and shares of Common Stock that were omitted from the Original Form 4 due to clerical error. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 05, 2020 Filed Aug 10, 2020 20:03 UTC Amendment |
Sandercock ColinSVP, General Counsel and Sec
|
Exercise / conversionCommon Stock | 13,374 | $7.50 | $100,305.00 |
DisclosureSEC source: 0001209191-20-045921 · doc4a.xml · nonDerivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 amends and restates the original Form 4 filed on August 7, 2020 (the "Original Form 4") to include 100 Stock Options and shares of Common Stock that were omitted from the Original Form 4 due to clerical error. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 20:51 UTC |
Sandercock ColinSVP, General Counsel and Sec
|
Exercise / conversionStock Option (right to buy) · Derivative | 201 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-20-045144 · doc4.xml · derivative · entry 6 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,374 Underlying: Common Stock · 201 shares Expires 2024-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 20:51 UTC |
Sandercock ColinSVP, General Counsel and Sec
|
SaleCommon Stock | 201 | $20.05 | $4,030.05 |
DisclosureSEC source: 0001209191-20-045144 · doc4.xml · nonDerivative · entry 4 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,125 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 20:51 UTC |
Sandercock ColinSVP, General Counsel and Sec
|
Exercise / conversionCommon Stock | 201 | $7.50 | $1,507.50 |
DisclosureSEC source: 0001209191-20-045144 · doc4.xml · nonDerivative · entry 3 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 20:50 UTC |
Suri AnishPresident and CSO
|
Exercise / conversionStock Option (right to buy) · Derivative | 400 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0001209191-20-045142 · doc4.xml · derivative · entry 8 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,800 Underlying: Common Stock · 400 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 20:50 UTC |
Suri AnishPresident and CSO
|
SaleCommon Stock | 400 | $20.14 | $8,056.00 |
DisclosureSEC source: 0001209191-20-045142 · doc4.xml · nonDerivative · entry 5 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,558 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.11 to $20.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 20:50 UTC |
Suri AnishPresident and CSO
|
Exercise / conversionCommon Stock | 400 | $6.42 | $2,568.00 |
DisclosureSEC source: 0001209191-20-045142 · doc4.xml · nonDerivative · entry 4 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:51 UTC |
Sandercock ColinSVP, General Counsel and Sec
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,425 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-20-045144 · doc4.xml · derivative · entry 5 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,575 Underlying: Common Stock · 6,425 shares Expires 2024-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:51 UTC |
Sandercock ColinSVP, General Counsel and Sec
|
SaleCommon Stock | 6,425 | $20.00 | $128,500.00 |
DisclosureSEC source: 0001209191-20-045144 · doc4.xml · nonDerivative · entry 2 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,125 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:51 UTC |
Sandercock ColinSVP, General Counsel and Sec
|
Exercise / conversionCommon Stock | 6,425 | $7.50 | $48,187.50 |
DisclosureSEC source: 0001209191-20-045144 · doc4.xml · nonDerivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:50 UTC |
Suri AnishPresident and CSO
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,800 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0001209191-20-045142 · doc4.xml · derivative · entry 7 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,200 Underlying: Common Stock · 3,800 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:50 UTC |
Suri AnishPresident and CSO
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001209191-20-045142 · doc4.xml · derivative · entry 6 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 2,000 shares Expires 2025-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning November 14, 2018. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:50 UTC |
Suri AnishPresident and CSO
|
SaleCommon Stock | 5,800 | $20.01 | $116,058.00 |
DisclosureSEC source: 0001209191-20-045142 · doc4.xml · nonDerivative · entry 3 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,558 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:50 UTC |
Suri AnishPresident and CSO
|
Exercise / conversionCommon Stock | 3,800 | $6.42 | $24,396.00 |
DisclosureSEC source: 0001209191-20-045142 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:50 UTC |
Suri AnishPresident and CSO
|
Exercise / conversionCommon Stock | 2,000 | $8.26 | $16,520.00 |
DisclosureSEC source: 0001209191-20-045142 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.